


Substitute Form PTO-1595
Attorney Docket No.: 14255-046001

RECORDATION FORM COVER SHEET PATENTS ONLY

Commissioner for Patents: Please record the attached original document(s) or copy(ies).

1. Name of conveying party(ies): Arcturus Bioscience, Inc. Additional name(s) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		2. Name and address of receiving party(ies): Molecular Devices Corporation 1311 Orleans Drive Sunnyvale, CA 94089-1136 United States of America Additional names/addresses attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	
3. Nature of conveyance: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other: Execution Date: April 3, 2006			
4. Application number(s) or patent number(s): If this document is being filed with a new application, the execution date of the application is: A. Patent Application No(s): 10/329,282 B. Patent No(s): Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
5. Name/address of party to whom correspondence concerning document should be mailed: Fish & Richardson P.C. 225 Franklin Street Boston, MA 02110		6. Total number of applications/patents involved: 1 7. Total fee (37 CFR §3.41): \$40 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to charge Deposit Account. 8. Deposit Account No.: 06-1050 Please apply any additional charges, or any credits, to our Deposit Account No. 06-1050, referencing Attorney Docket No. 14255-046001.	
DO NOT USE THIS SPACE			
9. Statement and Signature: <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i> Todd E. Garcia, Ph.D. Reg. No. 54,112 Name of Person Signing			
		 Signature	<u>10/20/06</u> Date
Total number of pages including coversheet, attachments and document:			

21435776.doc

CH \$40.00 061050 10329282

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

October 20, 2006 Date of Transmission

Mary J. Zynda Signature

Mary J. Zynda Typed Name of Person Signing Certificate

700292978

REEL: 018422 FRAME: 0404

PATENT ASSIGNMENT AGREEMENT

This **PATENT ASSIGNMENT AGREEMENT** (the "**Agreement**") is made and effective as of April 3, 2006, by and between Arcturus Bioscience, Inc., a California corporation ("**Seller**"), and Molecular Devices Corporation, a Delaware corporation ("**Purchaser**").

WHEREAS, pursuant to that certain Asset Purchase Agreement, dated as of April 3, 2006, by and between Seller and Purchaser (the "**Asset Purchase Agreement**"), Purchaser is acquiring from Seller all of Seller's right, title and interest in and to the Acquired Patents (as defined below).

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, Seller does hereby sell, assign, and transfer, to the Purchaser, its successors, legal representatives, and assigns, the Seller's entire right, title, and interest in:

- (a) the patents and patent applications set forth on **Schedule I** hereto (collectively the "**Acquired Patents**");
- (b) any provisional or other right to recover damages, including royalties, for prior infringement of any Acquired Patent; and
- (c) any patents of the United States or other countries that may be granted for or on any patent application included in the Acquired Patents, including continuation, divisional, continuation-in-part, reissues, re-examinations and extensions of any such application or patent.

The above-granted rights, titles, and interests are to be held and enjoyed by the Purchaser, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, as fully and entirely as the same would have been held and enjoyed by the Seller had this sale and assignment not been made.

Seller agrees and covenants that it will cooperate in any actions (i) necessary for Purchaser to effectuate the transfer and assignment of the Acquired Patents to Purchaser, including without limitation the execution of documents necessary to record the assignment with the appropriate government agencies, at Seller's reasonable cost and expense; (ii) necessary for Purchaser to prosecute, maintain, renew or register its rights, title and interests in and to the Acquired Patents, including without limitation United States and foreign registrations, at Purchaser's cost and expense; and (iii) brought to enforce and/or defend (including interference proceedings) the rights assigned to Purchaser pursuant to this Agreement against third parties, at Purchaser's cost and expense.

In the event of any conflict between this Agreement and the Asset Purchase Agreement, the Asset Purchase Agreement shall control. Nothing in this Agreement shall be deemed to amend or modify in any way any of the terms and conditions of the Asset Purchase Agreement or any rights or obligations of the parties thereto. Nothing in this Agreement shall enlarge or expand the representations and warranties of Seller related to the Acquired Patents contained in the Asset Purchase Agreement. This Agreement shall be construed in accordance with, and governed in all

respects by, the laws of the State of California (without giving effect to principles of conflicts of laws).


The Seller hereby requests the Commissioner of Patents to issue the Acquired Patents of the United States to the Purchaser for the sole use and behalf of the Purchaser, its successors, legal representatives, and assigns.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

PURCHASER:

MOLECULAR DEVICES CORPORATION

By: 

Print Name: Timothy A. Harkness

Title: Chief Financial Officer,
Senior Vice President
Finance and Operations

SELLER:

ARCTURUS BIOSCIENCE, INC.

By: _____

Print Name: _____

Title: _____

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

IN WITNESS WHEREOF, the undersigned has caused this Patent Assignment Agreement to be executed and delivered as of the date first above written.

PURCHASER: **MOLECULAR DEVICES CORPORATION**

By: _____

Print Name: _____

Title: _____

SELLER: **ARCTURUS BIOSCIENCE, INC.**

By: *A. Schuh*

Print Name: A. SCHUH

Title: CEO

[SIGNATURE PAGE TO PATENT ASSIGNMENT AGREEMENT]

Schedule I

All of the patents, patent applications and patent rights that are owned by Seller and that were used in or are used in the Life Sciences Business, or are currently being evaluated by Seller (as evidenced in Records) for use in the Life Sciences Business, including the patents, patent applications and patent rights identified in this **Schedule I**, and any counterparts, reissues, reexaminations, divisions, extensions, continuations and continuations-in-part of, and any other patents issuing therefrom or claiming priority thereto, any of the foregoing, in each case in any jurisdiction in the world.

“Life Sciences Business” shall mean any business operations of Seller related to the research, development, marketing and promotion of Seller’s instruments, reagents and disposable products for the molecular analysis of microscopic tissue samples, including the Specified Products, all as operated by Seller as of the date hereof. The “Life Sciences Business” expressly excludes Seller’s business operations that relate exclusively to research and development with a goal of identifying clinically useful biomarkers and commercialization of products and services that measure validated biomarkers for the purposes of reporting a diagnostic result to a human patient or physician. “Specified Product” shall mean Seller’s products for the molecular analysis of microscopic tissue samples including (a) all laser capture microdissection (LCM) instruments, (b) all reagents, disposable products and accessories used in connection with the LCM instruments, including reagents for nucleic acid isolation, amplification, detection and expression analysis, and micro-devices for low volume capture, extraction and purification of biological molecules, (c) all standalone products comprising any of the foregoing, and (d) all previous and future versions, translations, modifications, enhancements, improvements, upgrades, accessories, follow-ons or outgrowths of or to any of the foregoing or any related products currently under development. For clarity, the following Seller products are included in the Specified Products: Veritas™ XT Microdissection System, Veritas™ Microdissection System, PixCell® IIe LCM System, CapSure® LCM Caps, Paradise® Reagent System, Paradise® Whole Transcript RT Reagent System, RiboAmp® RNA Amplification Kit, RiboAmp® OA RNA Amplification Kit, RiboAmp® OA 1 Round RNA Amplification Kit, RiboAmp® HS RNA Amplification Kit, PicoPure® RNA Isolation Kit, PicoPure® DNA Extraction Kit, HistoGene® LCM Immunofluorescence Staining Kit, HistoGene® LCM Frozen Section Staining Kit, CapSure® HS LCM Caps, CapSure® Micro LCM Caps, ExtracSure™ Sample Extraction Devices, Miracol™ Purification Columns, PrepStrip™ Tissue Preparation Strips and AutoPix® Microdissection System. “Records” shall mean all books, records, files, data (whether in hard copy or electronic form), customer lists, customer records, copies of all documentation related to the accounts receivable generated from the Life Sciences Business, vendor records, research and development reports, scientific and technical documents (including original laboratory notebooks, data, vector maps, protocols, user manuals, and application notes that relate to the internal or commercial use of the Specified Products or otherwise to the Acquired Patents or Acquired Trademarks or that may be useful for prosecuting or enforcing the Acquired Patents or Acquired Trademarks) and advertising and promotional materials.

	Description	Jurisdiction	Registration / Application No.
118.	CONSUMABLE FOR LASER CAPTURE MICRODISSECTION	GB	1,021,700
119.	LASER CAPTURE MICRODISSECTION METHOD AND APPARATUS	DE	69,814,041
120.	CONSUMABLE FOR LASER CAPTURE MICRODISSECTION	DE	1,021,700
121.	CONSUMABLE FOR LASER CAPTURE MICRODISSECTION	FR	1,021,700
122.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	US	60/418103
123.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	AU	2003282608
124.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	CA	2500603
125.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	CN	200380103222.6
126.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	EP	03774797.9
127.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	JP	2004-543735
128.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	MX	PA/a/2005/003818
129.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	NZ	539124
130.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	PCT	PCT/US03/32345
131.	GENE EXPRESSION PROFILING FROM FFPE SAMPLES	US	10/329282
132.	NUCLEIC ACID AMPLIFICATION	US	60/257801
133.	NUCLEIC ACID AMPLIFICATION	US	60/298847
134.	NUCLEIC ACID AMPLIFICATION	EP	01993343.1
135.	NUCLEIC ACID AMPLIFICATION	PCT	PCT/US 01/50340
136.	NUCLEIC ACID AMPLIFICATION	US	6794141
137.	NUCLEIC ACID AMPLIFICATION	US	10/942252
138.	QUANTITATIVE IMMUNOHISTOCHEMISTRY (QIHC)	US	60/271344
139.	QUANTITATIVE IMMUNOHISTOCHEMICAL ASSAY FOR COVALENTLY MODIFIED OR STRUCTURALLY ALTERED PROTEINS	US	60/314697